
eurofins
Clinical Trial Solutions
Advancing Oncology Clinical Trials Through Integrated Global Solutions

eurofins | Clinical Trial Solutions

Central Laboratory–Led Safety Testing in Oncology Clinical Trials

Therapies often have narrow therapeutic windows, significant toxicity, and are increasingly administered in longterm or combination regimens. In this environment, safety testing is essential to distinguish treatment related toxicities from disease related symptoms, while protecting patients exposed to highly potent therapies. Centralization streamlines global sample collection and sample flow across global testing sites, ensures standardized testing, globally comparable data, realtime safety oversight, and regulatoryready outputs across all phases of oncology drug development. These elements are especially crucial in oncology, where sample integrity directly affects trial validity, and inherently, patient safety.



The landscape of oncology drug development is complex and rapidly evolving. From immuno-oncology to targeted therapies, the need for comprehensive, high-quality analytical services is paramount for success. Eurofins Clinical Trial Solutions is at the forefront, offering an integrated network of laboratories and scientific expertise to support your oncology clinical trials from early development to market.

Oncology studies are uniquely complex — involving biomarker driven designs, intensive safety monitoring, high data volume, and global execution challenges. Pathology, bioanalytical, biomarker, molecular genomics, and safety data are tightly interconnected.

We have made significant investments in industry-leading technologies and experienced scientific teams to support the growing demand for specialized services to support oncology trials. By deploying global centers of excellence, we provide custom, end-to-end solutions with an integrated team of experts across a broad range of applications.

Advanced Biomarker & Genomic Testing

Oncology increasingly depends on biomarkers driven study designs and molecular profiling requiring tumor biopsies, genetic sequencing, and diagnostic testing before and during enrollment. Eurofins Clinical Trial Solutions provides:

- **Bioanalytical testing**
- **Molecular Profiling & Biomarker Testing**
- **Gene Expression profiling [RNASeq, Nanostring]**
- **Next generation sequencing [NGS]**
- **Flow cytometry, histology, immunoassays**
- **ctDNA assays**
- **Comprehensive Immuno-Oncology and Cellular Therapy support**



eurofins | Clinical Trial Solutions

Oncology Drug Modality	Platforms	Examples of Assays
Small Molecules	Gene expression (RNASeq, NanoString) LC-MS (PK) NGS (tissue & ctDNA) Pathology (IHC) qPCR/ddPCR	Gene expression pathway modulation Pharmacokinetics by LC-MS Somatic mutation profiling (EGFR, KRAS, BRAF, DDR genes) Target expression by IHC Resistance mutation monitoring via ctDNA
mAbs/Immuno-Oncology (IO)	Flow cytometry Immunoassays (ELISA, ELISpot) NGS/Gene expression Pathology (IHC/IF) LC-MS/Ligand binding (PK/ADA)	Immune phenotyping (T, B, NK subsets) Cytokine release panels Immune gene expression signatures PD-L1 or immune marker IHC PK and anti-drug antibody (ADA) testing
Bispecific Antibodies/ T-Cell Engagers (TCEs)	Flow cytometry Immunoassays (ELISA, ELISpot) qPCR/ddPCR Pathology (IHC/IF)	T-cell activation and exhaustion markers Cytokine release syndrome (CRS) monitoring Immune cell proliferation assays Tumor target confirmation by IHC
Antibody-Drug Conjugates (ADCs)	Pathology (IHC/IF) LC-MS NGS Gene expression Immunoassays (PK/ADA)	Target expression and heterogeneity by IHC Total antibody and payload PK (LC-MS) Resistance mutation profiling (NGS) Payload response or stress gene signatures Anti-drug antibody detection
Cell/Gene Therapy	Flow cytometry qPCR/ddPCR NGS Immunoassays Pathology	CAR or transgene expression by flow Vector copy number and persistence (qPCR/ddPCR) TCR/BCR repetoire sequencing Cytokine monitoring (CRS risk) Tumor infiltration or tissue analysis
Radiopharma/ Radioligland Therapy	Pathology (IHC/IF) NGS qPCR LC-MS/Bioanalysis Immunoassays	Target expression (e.g., PSMA, SSTR, FAP) by IHC Companion biomarker profiling (NGS) PK and biodistribution assessment Organ toxicity and safety biomarkers Anti-drug or anti-vector antibody testing

eurofins | Clinical Trial Solutions

Partnering to Advance Therapeutic Innovation

Contact **ClinicalTrialSolutions@bcl.eurofins.com** for more information.